HPV (Human Papillomavirus)

Human Papillomavirus (HPV) infects epithelial cells, and its molecular biology plays a key role in the development of HPV-associated cancers. The viral genome encodes early proteins (E1, E2, E4, E5, E6, and E7) and late structural proteins (L1 and L2). The E6 and E7 oncoproteins, produced by high-risk HPV types, are central to the virus's oncogenic potential. E6 targets the tumor suppressor protein p53 for degradation, preventing apoptosis and allowing the survival of infected cells. E7 promotes the degradation of the retinoblastoma protein (pRb), leading to uncontrolled cell proliferation. Together, these actions disrupt normal cell cycle regulation and contribute to the development of HPV-associated cancers. Therapeutic approaches for HPV-related cancers include antiviral drugs and immunotherapies. Antiviral drugs, such as cidofovir and interferon, aim to inhibit viral replication and reduce the viral load. Immunotherapies, including immune checkpoint inhibitors, target the host's immune response to enhance the recognition and elimination of HPV-infected cells. Research into HPV molecular biology and the host immune response informs the development of novel therapeutic strategies. Vaccination remains a crucial component of HPV control, as preventing initial infections with high-risk HPV types is a primary means of reducing the incidence of associated cancers. Understanding the intricate molecular interactions between HPV and host cells is essential for developing targeted therapies and improving outcomes for individuals with HPV-associated diseases. Ongoing research aims to unravel the complexities of HPV pathogenesis, identify new therapeutic targets, and advance innovative approaches for the prevention and treatment of HPV infections and their associated cancers.